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The exact aetiology of Crohn’s disease is unknown, though it is
clear from early epidemiological studies that a combination of
genetic and environmental risk factors contributes to an in-
dividual’s disease susceptibility. Here, we review the history of
gene-mapping studies of Crohn’s disease, from the linkage-based
studies that ﬁrst implicated the NOD2 locus, through to modern-
day genome-wide association studies that have discovered over
140 loci associated with Crohn’s disease and yielded novel insights
into the biological pathways underlying pathogenesis. We describe
on-going and future gene-mapping studies that utilise next gen-
eration sequencing technology to pinpoint causal variants and
identify rare genetic variation underlying Crohn’s disease risk. We
comment on the utility of genetic markers for predicting an in-
dividual’s disease risk and discuss their potential for identifying
novel drug targets and inﬂuencing disease management. Finally,
we describe how these studies have shaped and continue to shape
our understanding of the genetic architecture of Crohn’s disease.
 2014 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/3.0/).Introduction
Crohn’s disease is a chronic inﬂammatory disease of the gastrointestinal tract affecting 26–200 per
100,000 in European populations [1]. Along with ulcerative colitis, it is one of the two major forms of
inﬂammatory bowel disease (IBD). The exact causes of Crohn’s disease are unknown, though it is likely. Anderson).
evier Ltd. This is an open access article under the CC BY license (http://
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[2]. There is currently no known cure and disease is managed by a combination of immune-suppressing
medications, dietary changes or surgery.
Family and twin studies
Epidemiological observations in the 1930s ﬁrst suggested an inherited component to Crohn’s dis-
ease risk. Familial clustering showed that 2–14% of patients have a family history of CD [3], while
estimates of the sibling relative risk ratio (the ratio of disease risk among siblings of patients compared
with that in the general population, i.e. the population prevalence) ranged from 15–42 [3]. The vari-
ation in these estimates highlights the difﬁculty in obtaining accurate heritability measures for rela-
tively rare diseases such as Crohn’s. Confounders also include inconsistent study design (e.g. only
counting ﬁrst degree relatives rather than all relatives), sample selection bias (e.g. using hospital cases
that are likely to have a more severe form of the disease than the general Crohn’s population), and
variation in disease prevalence rates, both between different populations and over time [3–7].
Moreover, these observations do not in themselves suggest a role for genetics in disease risk because
familial resemblance can also be a consequence of shared environmental factors.
Twin studies have now provided compelling evidence for a signiﬁcant genetic component to
Crohn’s disease risk. The twin design assumes that the environmental component to phenotypic
variation is the same between monozygotic (MZ) and dizygotic (DZ) twins, and thus the difference in
disease concordance rates between sets of MZ and DZ twin pairs can be used to estimate the additive
genetic, shared environmental and unique environmental components of disease risk. A meta-analysis
of six twin studies with a combined set of 112 MZ and 196 DZ twin pairs reported concordance rates of
30.3% and 3.6% respectively [8], indicating that a large component of Crohn’s disease risk is indeed
genetic. Together, these family and twin studies provided the motivation for the ﬁrst wave of gene-
mapping studies throughout the mid-1990s aimed at identifying the regions of the genome that
contribute to Crohn’s disease risk.
Linkage studies
A linkage study identiﬁes regions of the human genome underlying disease susceptibility by testing a
series of marker alleles for cosegregation (linkage) with disease status across a number of families (or a
single large family with multiple affected members). Owing to the large size of chromosomal segments
segregating within a typical family, around 300 evenly distributed microsatellite markers are usually
sufﬁcient to capture themajority of positionswhere the chromosomes of the parents crossed over during
meiosis (recombinationevents). The evidence for linkage in a region is evaluatedbymetrics such as a LOD
(logarithm of odds) score, which compares the probability that the genotyped marker and the hypo-
thetical disease locus are inherited together in the observed data versus the probability of observing the
cosegregationpatternpurely bychance. A typical linkage studywill report all lociwith LOD scores greater
than three,which corresponds to thedata being1000 timesmore likely to arisedue to cosegregationwith
disease than by chance [9]. By the mid-nineties, linkage studies had proven to be a robust means of
identifying highly penetrant loci underlying monogenic disease such as cystic ﬁbrosis [10] and Hun-
tington’s disease [11] and the utility of the method for mapping complex disease loci was increasingly
beingexplored. From1996 to 2004,11 linkage studieswereperformed for Crohn’s disease (reviewedhere
[7]), the largest of which was a meta-analysis consisting of 1068 affected relative pairs [12].
The ﬁrst Crohn’s disease linkage study in 1996 identiﬁed a signiﬁcant disease susceptibility locus on
chromosome 16 (dubbed IBD1) [13]. This result was conﬁrmed in subsequent studies [14–20] and in
2001 the speciﬁc causal mutations that underlie risk were localised to three low frequency coding
variants (R702W, G908R and L1007fs) within the NOD2 gene (at that time, also known as CARD15) [21–
25]. These three variants individually had odds ratios (ORs) of 2–4 in heterozygotes and 20–40 for
homozygotes, and at least onemutationwas present in 30–40% of Crohn’s disease cases comparedwith
6–7% in European controls [7].
Spurred on by the discovery of NOD2, additional linkage studies of Crohn’s disease (and other
common complex diseases) were undertaken; The results of these studies were largely disappointing,
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contrast toMendelian diseases, were unlikely to be driven by the highly penetrant risk loci that linkage
is well powered to detect. In 1996 a seminal paper was published in Science proposing that complex
diseases are underpinned by common variants of modest effect [26]. The authors demonstrated that,
for a risk allele of 50% frequency and OR of 1.5, around 18,000 affected sib-pairs would be needed to
detect the locus via linkage. In contrast, they reported that less than 1000 trios would be needed to
detect such a locus adopting the transmission/disequilibrium association test of Spielman et al. [27].
Technological limitations at the time restricted the immediate uptake of the association study design;
such studies require that a causal variant (or another variant in high linkage disequilibrium (LD) to the
causal variant) is directly genotyped in order to detect a signiﬁcant signal of association.
Candidate gene association studies
While it was infeasible to test for association at markers across the entire genome, markers within
individual genes were often tested for association. Genes were selected based on a priori knowledge of
biological function or because the lay within a region implicated through linkage analysis. These
candidate gene studies typically involved genotyping a set of markers within a gene of interest in a
sample of disease cases and controls, and testing for statistically signiﬁcant differences in allele fre-
quencies between the two groups. Other study designs such as transmission disequilibrium tests in
parent-offspring trios were also often used.
Results from the majority of candidate gene studies of Crohn’s disease were disappointing, with
initial ﬁndings often failing to replicate in subsequent studies [28–31]. A combination of small sample
sizes, false-positive association, publication bias and failure to account for multiple comparisonsmeant
that as many as 95% of ﬁndings from candidate gene studies of complex traits during this erawere false
[32,33]. In some cases, the lack of power in these studies meant that variants in genes that later became
established risk loci were missed altogether (for instance, IL10 [34,35]). Ultimately however, it would
take a combination of technological advances and a greater appreciation of the need for much larger
sample sizes to make the identiﬁcation of bona ﬁde risk loci routine.
Genome-wide association studies
In the early 2000s, alongwith the closing phases of HumanGenome Project, concurrent efforts were
underway to gauge the extent of human genetic variation at the population level. Projects such as the
SNP Consortium and dbSNP had catalogued over 1.4 million single nucleotide polymorphisms (SNPs)
by 2001 [36,37]. It was found that common SNPs in physical proximity formed LD blocks punctuated by
hotspots of recombination [38]. These correlation patterns were further characterised through the
International Hapmap Project, which by 2007 had identiﬁed a further 3.1 million SNPs across 270
individuals from three distinct ancestry groups [39]. At the same time, technological advances in
microarray technologies made possible the cost-effective genotyping of hundreds of thousands of SNPs
spread throughout the genome [40]. The patterns of LDmeant that these arrays could effectively survey
the majority of common genetic variation in a population by directly genotyping only a fraction of the
total number of variants in the genome. In Europeans and East Asians, around ﬁve million common
SNPs (thosewithminor allele frequency greater than 5%) can be almost entirely tagged by a selection of
approximately 500,000 SNPs [41,42]. Together, these advances paved the way for researchers to
perform genome-wide association studies (GWAS) in order to identify loci associated with complex
traits or disease risk.
Genome-wide association studies typically look for statistically signiﬁcant differences in allele (or
genotype) frequencies between a large number of diseased individuals and population controls across
hundreds of thousands of SNPs spread throughout the genome. The SNPs that show signiﬁcant asso-
ciation with disease status point to regions of the genome likely to harbour disease relevant genes.
Unlike linkage studies, GWAS are not restricted to sibling pairs and families, and also have generally
greater statistical power to detect associated loci of small to moderate effect sizes (Fig. 1) [26]. Due to
patterns of LD, SNPs that are associated with disease are unlikely to be the true causal variant, but
rather are correlated with (‘tag’) an untyped causal variant. In addition, genotypes at SNPs that were
Fig. 1. The genetic architecture of Crohn’s disease. Known Crohn’s disease risk variants are plotted according to their minor allele
frequency and odds ratio (OR) [59]. The size of the circles represents the amount of variance in Crohn’s disease liability explained by
that variant. The red, blue and black lines represent the minimum OR and allele frequency for a locus for which a linkage study with
3000 individuals, GWAS with 3000 individuals and GWAS with 50,000 individuals respectively will have >80% statistical power to
detect [26,108]. P-value thresholds for power calculations were set to P < 104 for linkage and P <5  108 for GWAS. The dashed
lines represents the allele frequency spectrum of variants that are typically poorly captured on GWAS microarrays (minor allele
frequencies less than 1%).
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from a representative reference set of haplotypes [39,45,46], allowing for individual studies using
different genotyping platforms to be effectively combined into meta-analyses.
The ﬁrst Crohn’s disease GWAS was conducted in a Japanese population in 2005, and identiﬁed
TNFSF15 as a susceptibility locus [47]. This was followed by a rush of studies from 2006 to 2008 [48–
55], each including approximately 500–2000 Crohn’s disease cases and a similar number of controls
genotyped at 100,000–600,000 SNPs. Unlike linkage studies, the development of standardised
quality control protocols along with strict statistical criteria for claiming association and replication
[55,56] meant the vast majority of SNPs that achieved genome-wide statistical signiﬁcance (asso-
ciation p-value <5  108) were true positives. The genes and pathways identiﬁed by these early
GWAS provided many insights into the biological processes underlying Crohn’s disease. Most notably,
associations at ATG16L1 and IRGM ﬁrst suggested a role for autophagy in disease pathogenesis
[2,48,52]. Other genes involved in both the innate (TLR4, CARD9, IL23R, STAT3) and adaptive immune
system (HLA, TNFSF15, IRF5, PTPN22) pathways were also implicated [57]. GWAS have also shed light
on the genetic overlap between Crohn’s and other immune-related diseases. Around 30% of asso-
ciated variants in these initial studies were shared with ulcerative colitis, while close to 50% of loci
are shared with at least one other immune-mediated disease such as type 1 diabetes, coeliac disease
or rheumatoid arthritis [58]. Unlike many of these diseases, genes in the human leucocyte antigen
(HLA) region only confer a modest effect on Crohn’s disease risk (ORs 1.1–1.2). This is in contrast to
ulcerative colitis, where several variants in HLA-B make the largest contribution to genetic risk (ORs
1.4–1.5) [59].
These early GWAS showed that, with the exception of NOD2, the typical effect size of a Crohn’s
susceptibility locus was modest (OR < 1.3), such that the loci identiﬁed only explain a fraction of the
known genetic component of Crohn’s disease risk (highlighting the ‘missing heritability problem’
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frequency less than 1%) and structural variants that are not well-captured on the current generation of
GWASmicroarrays, a substantial number of common variants will have even smaller effects than those
identiﬁed, requiring much larger sample sizes to detect [62]. Indeed, for Crohn’s disease, it has been
estimated that 22% of the differences in individual disease risk seen in the population (variance in
disease liability) can be explained by common variants tagged on microarrays [63] – more than double
that explained by known risk loci [64].
An appreciation of the need for larger sample sizes led to the creation of the International IBD
Genetics Consortium (IIBDGC) (http://www.ibdgenetics.org/) to bring together investigators and
GWAS datasets from IBD genetics groups around the world. From 2008 to 2012 the IIBDGC published
three genome-wide association study meta-analyses [59,64,65]. The ﬁrst of these in 2008 combined
data for w13,000 individuals from three previously published GWAS and identiﬁed 21 new Crohn’s
susceptibility loci [64]. This was followed two years later by a meta-analysis of six GWAS with a total
sample size ofw50,000 individuals where 30 new loci were identiﬁed, bringing the total count to 71
[65]. The most recent meta-analysis in 2012 included 75,000 individuals and doubled the number of
known Crohn’s susceptibility loci to 140 (Fig. 2) [59]. Along with the 23 loci associated with ulcerative
colitis, the total number of 163 inﬂammatory bowel disease associated loci represents the most for any
complex disease to date. These loci were enriched for genes involved in primary immunodeﬁciencies
and this enrichment was even more striking for genes harbouring Mendelian susceptibility to myco-
bacterial disease (MSMD) risk variants, where six of the eight genes linked to MSMD overlap with IBD.
Similarly, seven of the eight genes known to be associated with leprosy are also shared with IBD, and
altogether, 66 IBD loci are shared with other immune-mediated diseases. These overlaps suggest that
selection pressures driven by mycobacterial infection may have shaped the genetic architecture of
Crohn’s disease.
The results of Jostins et al. [59] also highlighted the role of noncoding variation in disease risk. Many
of these variants are likely to affect the amount that a gene is expressed (gene regulation) rather than
code the protein product. Only nine of the 140 associated loci exclusively harbour variants within
coding regions of genes (IL23R, GPR35, CD6, MUC19, GPR65, ZNF831, ADAM30, NOD2, FUT2) while an
additional 13 have variants encompassing both coding and noncoding regions (UBQLN4, ITLN1,
FCGRA2A, MST1/BSN, SLC22A4, REV3L, CARD9, ZPBP2/GSDMB, TUBD1, CD226, YDJC, ATG16L1, LACC1).
Altogether, 51 loci overlap variants with a known effect on gene expression (eQTLs – expression
quantitative trait loci; Fig. 3). Most studies that detect eQTLs have been limited to only a few hundred
individuals in only a small number of cell types (liver, brain, ﬁbroblasts, monocytes, T cells and lym-
phoblastoid cell lines) [66,67]. The overlap between eQTLs and disease-associated variants will in-
crease as more eQTL studies are performed across larger samples sizes and across different cell types,
especially those involved in the immune system in the case of Crohn’s disease.
Targeted genotype arrays
A feature of the latest IIBDGC meta-analysis was the use of the Immunochip custom genotyping
array for replicating signals identiﬁed in the original GWAS meta-analysis. The Immunochip was
designed after the ﬁrst wave of GWAS meta-analyses to aid in the replication, ﬁne-mapping and dis-
covery of loci associated with inﬂammatory and autoimmune diseases [68]. To take advantage of the
pervasive genetic overlap between many of these diseases, the Immunochip contains a dense panel of
w130,000 SNPs located in 186 regions with known associationwith one or more of 12 immune-related
diseases. SNPs within the regions were ascertained via dbSNP, the 1000 Genomes project (February
2010 release), and autoimmune disease resequencing projects. While not all SNPs passed the Illumina
design process and made it onto the microarray, the Immunochip provides unprecedented coverage of
common, low-frequency and rare variants across these 186 genomic regions. A further 50,000 SNPs
that were suggestively signiﬁcant in the original GWAS studies were also included. This panel served as
the replication set of SNPs in Jostins et al., where over 40,000 IBD cases and controls were genotyped.
The cost-effectiveness of the Immunochip (atw20% that of a GWAS microarray at the time) allows for
studies with much larger sample sizes than GWAS and also enables powerful disease subphenotype
and cross-disease comparisons [69].
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The causal variants that underlie themajority of loci discovered through GWAS remain unidentiﬁed.
An associated locus will often consist of dozens of correlated SNPs in high LD spanning across many
genes, with very similar association signals. In the 140 loci associated with Crohn’s risk, the number of
SNPs that are tagged (r2 > 0.8) by the main GWAS SNP range from 1 to 306 per locus (median 13).
Narrowing these down to a single causal variant is difﬁcult and will initially require a combination of
many complementary approaches. Firstly, much larger sample sizes will be required to differentiate
statistical signals at causal variants over their highly correlated neighbours. Secondly, as patterns of LD
differ between different ancestral groups, obtaining samples frommultiple populations can narrow the
associated region for risk loci that are shared across populations. Thirdly, combining functional genetic
information with association results allows variants with relevant annotations to be up-weighted in
association analyses. Data from projects such as ENCODE [70] and GTEx [71] provide rich functional
genomic information that can be readily integrated with GWAS results. In addition to providing
functional candidates, these functional annotations can also uncover biological mechanisms through
which variants act, either through the speciﬁc cell type or functional element [72–74]. Under the
auspices of the IIBDGC, efforts to ﬁne-map associated loci using the Immunochip are underway, along
with transethnic studies of IBD across European and non-European populations. Ultimately, the direct
modelling of these variants in cell lines and model organisms may be required for ﬁnal conﬁrmation of
causality. Emerging technologies such as DNA editing through CRISPR and engineering induced
pluripotent stem cells are likely to play an important role [75–77].
The IRGM locus exempliﬁes some of the challenges in identifying causal variants. The SNP initially
associated with disease was later found to be in perfect LD with a 20 kb deletion upstream of IRGM
[52,78]. This deletion was thought to be causal because it affects the expression of IRGM, which in turn
regulates the efﬁciency of autophagy. A later study showed, however, that this deletion is one of several
highly correlated Crohn’s disease associated variants in the region that affect IRGM expression, none of
which can reasonably be ruled out as causal [79]. Furthermore, the variants are also not associatedwith
Crohn’s disease in the Japanese population, suggesting either European-speciﬁc gene-environment
interactions or the presence of an untyped causal variant that arose after the European-Asian popu-
lation split [79].
Next generation sequencing
The role of rare variants in complex diseases is currently an important area of focus in human
genetics. High-throughput discovery and accurate genotyping of rare variants has recently been made
feasible through large reductions in the cost of next-generation sequencing. Often cited as a possible
explanation for missing heritability, rare variants are in theory likely to have much larger effect sizes
than common variants due to purifying selection maintaining damaging alleles at low frequencies [61].
Indeed, loci that are associated with complex disease are enriched for rare variants that cause known
Mendelian disorders and it has been suggested that recessive variants confer risk to related complex
diseases when the carrier is heterozygote [80]. Independent rare variant associations are also often
found in genes with known common associated variants [81–83].
Since the rare allele of individual rare variants are observed so infrequently, single variant tests of
associationwill be underpowered for all but themost highly penetrant alleles. For instance, for an allele
that doubles disease risk (OR ¼ 2) and has a frequency of 0.1%, nearly 60,000 cases and a similar
number of controls will be required for the variant to reach genome-wide signiﬁcance. To increase
power to detect association, rare variants are often aggregated based on characteristics such as theirFig. 2. The Crohn’s disease genome. Known Crohn’s disease risk loci are shown according to their location on the long or short
arms of chromosomes. The size of each locus indicates the proportion of variance in Crohn’s disease liability explained by that locus
[59]. Several notable genes are marked. Parentheses next to gene names denote the number of independent risk variants within the
locus. The number above each chromosome is the ratio of the total amount of variance explained by that chromosome vs the ex-
pected number given the chromosome’s size. Sex chromosomes were excluded as no loci have been conclusively implicated, largely
due to these chromosomes being overlooked from most GWAS.
Fig. 3. Proportion of noncoding, nonsynonymous and known eQTLs among known 140 Crohn’s disease risk loci [59]. A locus is
labelled as nonsynonymous if the lead SNP is in high linkage disequilibrium (LD; r2 > 0.8) with a nonsense or missense mutation.
Similarly, loci with eQTLs were marked if the lead SNP is in high LD with a known eQTL in studies of liver, brain, ﬁbroblasts,
monocytes, T cells and lymphoblastoid cell lines [66,67].
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have been proposed [84–87] along with methods for meta-analysis and replication [88–90].
The degree to which such variants contribute to Crohn’s disease heritability is unclear, and the
results from early large scale sequencing studies targeted at known susceptibility genes have been
disappointing [81,91,92]. These studies typically involved sequencing the coding regions of several
candidate genes in a few hundred cases and controls followed by the direct genotyping of putatively
associated variants in a much larger replication cohort. Coding regions are targeted because the
functional consequences of variants in these regions are much better understood than those in non-
coding parts of the genome. In addition, coding variants are hypothesized to have larger effect sizes
given their direct impact on protein product and are generally more evolutionarily conserved than
noncoding variants [93]. Momozawa et al. [81] initially sequenced 63 candidate genes in 112 Crohn’s
disease cases and 112 controls with replication in an additional 288 to 928 cases and 288 to 1216
controls, and identiﬁed four independent associations in IL23R, although only one of these exceeded
genome-wide signiﬁcance. Similarly, Rivas et al. [92] sequenced 56 genes in 350 cases and 350 controls
with follow-up genotyping in 16,054 cases and 17,575 controls, and identiﬁed 12 independent rare
variant associations across seven genes, of which two (coding variants in NOD2 and CARD9) exceeded
genome-wide signiﬁcance. These three genome-wide signiﬁcant variants were included on the
Immunochip and subsequently conﬁrmed in Jostins et al. [59] using around 75,000 samples. However,
a recent sequencing study of 25 candidate genes across 41,911 individuals, of which 3271 were Crohn’s
disease cases, failed to identify any novel associations [91]. A natural extension for candidate gene
sequencing studies is to sequence the entire exome of cases and controls. A recent exome sequencing
study in 42 Crohn’s cases with follow-up genotyping in 9348 cases and 14,567 controls found sug-
gestive rare variant associations in PRDM1 [94]. Again, the variant failed to reach genome-wide sig-
niﬁcance and other whole exome studies with much larger sample sizes are currently underway.
The sobering results from these studies highlight the challenges in rare variant association studies.
As it is currently not economically feasible to perform high coverage whole-genome sequencing in a
large number of cases and controls, compromises often need to be made in terms of the number of
genomic regions covered and the number of individuals. The majority of loci identiﬁed in GWAS lie in
noncoding regions (Fig. 3), which have been overlooked by the current generation of sequencing
studies. A large number of rare noncoding variants will play a role in gene regulation, though it remains
to be seen whether their effects are large enough to be a major contributor to disease susceptibility.
Performing burden tests across rare variants in regulatory regions such as promoters and enhancers
may show promise. Most importantly, the sample sizes used in these sequencing studies have thus far
simply been insufﬁcient to robustly identify rare variant associations. Under certain assumptions about
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may be required in order to ﬁnd these signals, along with an equally large number for replication [95].
In addition to candidate gene and whole-exome sequencing, the next few years will also see the
emergence of low-coverage whole-genome sequencing studies. While sequencing individuals at deep
coverage (>30) is required to obtain accurate individual genotype calls, low coverage sequencing
(less than 6) and jointly calling shared (non-private) variants across many thousands of individuals is
a cost effective method for discovering rare variants. For instance, for a SNP with frequency 0.2% to be
discovered, over 2000 individuals need to be sequenced at 30 coverage (60,000 genomes). In
contrast, the same SNP can be identiﬁed inw3000 individuals sequenced at 4 (12,000 genomes) – a
ﬁve-fold reduction in sequencing cost [96] and, with more sequenced individuals, greater power to
detect associations. The obvious advantage of these study designs over targeted or whole-exome
sequencing is that they survey the entire genome rather than individual regions. Additionally, large
cohorts of sequenced individuals can be used as reference panels to impute rare variants into new and
existing GWAS datasets at much greater accuracy than existing panels. Over the course of 2014–15, it is
expected that over 30,000 individuals, of which w5000 are IBD cases, will be sequenced at low-
coverage. Imputing the millions of new variants discovered from this set into w25,000 Crohn’s dis-
ease cases (of which w15,000 have already been genotyped as part of GWAS) along with sufﬁcient
replication will, for the ﬁrst time, enable studies with sufﬁcient power to begin detecting associations
at SNPs with frequencies in the order of 0.1–1% and ORs of 2–3 (Fig. 2).
Genetic prediction
In addition to gaining a better understanding of disease biology, genetic information can also
potentially be used for disease risk prediction. Prediction methods for complex diseases typically
involve assigning a risk score to an individual based on their genotypes and previously estimated effect
sizes (for instance, ORs from GWAS) across risk alleles. Risk alleles can be assigned not only based on
known associations, but also include nominally associated variants. Prediction accuracy can be eval-
uated by methods such as the receiver operating characteristic curve (ROC), which estimates the true
and false positive rates of the predictor at various risk score cut-offs [97]. The area under the ROC (AUC)
is the probability that for a randomly selected pair of diseased and healthy individuals, the diseased
individual will have a higher risk score. An AUC of 0.5 means that the prediction method is no better
than chance, while a value of onemeans that themethod perfectly discriminates between diseased and
healthy individuals.
In Crohn’s disease, genetic risk prediction is still in its infancy and does not currently offer much in
terms of clinical utility. Estimates of AUC using just family history of disease, genetic risk loci or the two
together range from 0.56 to 0.74 [98,99]. Including risk factors such as smoking and age into the risk
model may improve the AUC. Nevertheless, given its high heritability, the theoretical maximum
possible AUC assuming that all Crohn’s disease risk loci have been identiﬁed and effect sizes are
accurately measured is estimated to lie between 0.96 and 0.98 [100,101]. However, while this ﬁgure
seems high, the utility of genetic prediction is limited given the low prevalence of Crohn’s disease. Even
assuming a generous disease prevalence estimate of 1% and AUC of 0.98, less than 12% of individuals
who test positive (using a sensitivity cut-off of 0.93) will develop disease [100]. Increasing the
threshold will increase the proportion of positively identiﬁed individuals but also exclude a higher
number of cases from being identiﬁed. Genetic prediction may offer better value in existing patients
through informing best course of treatment, though greater knowledge of how risk loci affect these
subphenotypes will be required [102].
Crohn’s disease subphenotypes
Genetic studies have begun to shed light on loci associatedwith Crohn’s disease subphenotypes such
as disease location and clinical course. These studies often focus on one or more candidate genes with a
subphenotype of interest [102–104] or can survey the whole genome in the same way as a GWAS [105].
Oneof the strongest signals associatedwith clinical outcomehasbeen codingvariants inNOD2,which are
strongly predictive for ileal disease, stenosis, ﬁstula and Crohn’s related surgery [102]. It has been
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coding variant in FOXO3Awas also recently implicated with Crohn’s disease prognosis [104]. The minor
allele was found to be signiﬁcantly more common in indolent patients (deﬁned as having disease for
longer than four years butwith no immunomodular or intestinal resections required) than patients with
frequent ﬂaring or a complicated course of treatment (where two or more immunomodular therapies/
intestinal resections were required). Despite not being associated with Crohn’s disease susceptibility
itself, FOXO3A variants are thought to affect disease outcome via regulation of IL7 and IL2 signalling
pathways, whose expression patterns correlate with clinical course of autoimmune diseases [107]. The
study demonstrated how integrating GWAS data into functional genomic, model organism and clinical
information can uncover basic biological pathways that are associated with disease outcome.The genetic architecture of Crohn’s disease
Putting together the results from linkage, genome-wide association and sequencing studies, the
genetic architecture of Crohn’s disease represents that of a typical multifactorial complex trait where a
combination of multiple genes, along with the environment, lead to disease. With few exceptions,
individual risk loci confer only a modest effect on disease susceptibility and together, the known loci
explainw13% of variation in disease liability [59]. The majority of the genetic contribution to disease
risk remains to be explained. Nevertheless, it is perhaps safe to say that that nearly all variants with
frequency greater than 5% and ORs greater than 1.2 in individuals of European ancestry have been
identiﬁed and the remaining genetic contribution will arise from a combination of common variants
with ever-smaller effect sizes and rare variants [62]. In addition, all variants with large effects (OR > 3)
and frequency greater than 1% have also been uncovered by GWAS and linkage studies (Fig. 1). Future
sequencing studies will shed light on the exact effect size distribution of rare variants. Finally, it should
be emphasised that locus discovery is not an end in itself. Challenges remain in taking what we’ve
learned from genetic studies to build more complete models of disease pathogenesis and ultimately
translating these into better patient outcomes.Practice points
- Early familial observations and twin studies demonstrated that there is a significant genetic
contribution to Crohns disease risk.
- Identifying the specific genes responsible for disease will provide insights into disease
biology and potential therapeutic targets.
- The discovery of NOD2 variants demonstrated the potential of linkage and candidate gene
studies to identify risk loci, though subsequent efforts were largely unsuccessful.
- Since 2006, genome-wide association studies have established over 140 loci associated with
Crohns disease risk.
Research agenda
- Fine-mapping studies and direct experimental work will be required to identify the causal
variants and biological mechanisms that underlie Crohns disease risk loci.
- Whole-genome sequencing studies will help elucidate the contribution of rare and low-
frequency variants to disease risk.Acknowledgements
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